Thomas Obrien
Pulmonary Disease · Kissimmee, FLNPI 1396700803
Payments from drug & device makers
Across 893 payments — averaging $1043.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$192K
- GSK$159K
- AstraZeneca$139K
- Kadmon Corporation LLC$117K
- Philips North America LLC$104K
- United Therapeutics Corporation$86K
- plus $135K from 40 others
Across 16 payments — averaging $312.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$931,689 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Kissimmee
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.